Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial
VANCOUVER, BC, May 11, 2021 /CNW/ - Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)("Numinus" or the "Company"), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, and Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, have met another early milestone in the development of an initial all-natural psilocybin extract.
Optimi and Numinus, through Impact Clinical Trials Accelerator at the University of Calgary ("Impact"), have ...
Read The Full Article On StockStreetNews.com
Get early insight on hidden secret gems on StockStreetNews . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by StockStreetNews is subject to our Terms Of Use and Disclaimer .
For further details see:
Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application